Landmark Studies in Uveitis
Neil Onghanseng, MD1,2, Franz Marie Cruz, MD3,4,5
1DOH Eye Center, East Avenue Medical Center, Quezon City
2Department of Ophthalmology, Makati Medical Center, Makati City
3College of Medicine, University of the Philippines-Philippine General Hospital, Manila
4International Eye Institute, St. Luke’s Medical Center, Quezon City
5Peregrine Eye and Laser Institute, Makati City
Correspondence: Franz Marie Cruz, MD
Peregrine Eye and Laser Institute, 5/F Morning Star Center,
347 Sen. Gil Puyat Ave, Brgy Bel-Air, Makati City
Disclaimer: The authors report no conflicts of interest or financial disclosures from the devices and drugs mentioned in the paper.
This paper provides the summaries on nine (9) important and clinically relevant publications in the field of uveitis. The first is on the standardization of uveitis nomenclature, more popularly known by its acronym – SUN, which was a result of an international workshop participated by uveitis experts in 2004. Five (5) papers were large, multicenter, clinical trials that demonstrated safety and efficacy of two (2) corticosteroids delivery devices (dexamethasone implant [Ozurdex] and fluocinolone acetonide implant [RetisertTM]) and one (1) immunomodulatory drug (adalimumab). The POINT trial compared various delivery approaches when using corticosteroids for the treatment of uveitic macular edema. The FAST trial compared two (2) durable and commonly-prescribed steroid-sparing immunosuppressants, methotrexate and mycophenolate mofetil, for the treatment of non-infectious uveitis. Lastly, the SITE study, which was a large retrospective cohort study, determined the risks of overall and malignancy-related deaths among patients with inflammatory eye diseases receiving systemic immunosuppressants. Findings of these studies provide basis and rationale for the care and management of patients with uveitis and lay the groundwork for future research.
Keywords: uveitis, clinical trial, review, inflammatory eye disease, corticosteroids
Philipp J Ophthalmol 2021;46:60-71